Literature DB >> 9343144

Moclobemide and selegeline in the treatment of depression in Parkinson's disease.

E N Steur, L A Ballering.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9343144      PMCID： PMC2169782          DOI： 10.1136/jnnp.63.4.547

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  13 in total

1.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Striatal mechanisms underlying movement, reinforcement, and punishment.

Authors:  Alexxai V Kravitz; Anatol C Kreitzer
Journal:  Physiology (Bethesda)       Date:  2012-06

Review 3.  Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?

Authors:  Atbin Djamshidian; Sabine Bernschneider-Reif; Werner Poewe; Andrew J Lees
Journal:  Mov Disord Clin Pract       Date:  2015-10-06

4.  Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Cynthia Kwan; Imane Frouni; Dominique Bédard; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-07-03       Impact factor: 3.000

5.  Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Imane Frouni; Cynthia Kwan; Dominique Bédard; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-29       Impact factor: 3.000

Review 6.  Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Authors:  Eva Schaeffer; Daniela Berg
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

Review 7.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  MAO-inhibitors in Parkinson's Disease.

Authors:  Peter Riederer; Gerd Laux
Journal:  Exp Neurobiol       Date:  2011-03-31       Impact factor: 3.261

9.  Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease.

Authors:  Rakhee Krishna; Manal Ali; Ahmed A Moustafa
Journal:  Front Aging Neurosci       Date:  2014-07-25       Impact factor: 5.750

10.  Born to yawn? Understanding yawning as a warning of the rise in cortisol levels: randomized trial.

Authors:  Simon Bn Thompson; Phil Bishop
Journal:  Interact J Med Res       Date:  2012-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.